Form 4: Vertex Pharmaceuticals SVP Kristen Ambrose Reports Stock Award
SEC Form 4 Filing
Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reports the acquisition of 2,080 shares of common stock through a restricted stock unit award.
Summary
- On February 12, 2025, Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reported a transaction.
- She acquired 2,080 shares of Vertex Pharmaceuticals common stock through a restricted stock unit award.
- The price per share was $0.
- Following the transaction, Ms. Ambrose beneficially owns 12,033 shares of common stock.
- The restricted stock units vest in installments beginning on February 24, 2026.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding stock ownership, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders reporting transactions in their company's stock, providing transparency to the market.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 02/12/2025 | Date of transaction: Kristen Ambrose acquired 2,080 shares of common stock. |
| 02/14/2025 | Date of signature on the Form 4 filing. |
| 02/24/2026 | Vesting start date for the restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.